AU724645B2 - Use of sibutramine analogues to lower lipid levels - Google Patents

Use of sibutramine analogues to lower lipid levels Download PDF

Info

Publication number
AU724645B2
AU724645B2 AU47741/97A AU4774197A AU724645B2 AU 724645 B2 AU724645 B2 AU 724645B2 AU 47741/97 A AU47741/97 A AU 47741/97A AU 4774197 A AU4774197 A AU 4774197A AU 724645 B2 AU724645 B2 AU 724645B2
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
density lipoprotein
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47741/97A
Other languages
English (en)
Other versions
AU4774197A (en
Inventor
Stephen Paul Jones
Peter Finian Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of AU4774197A publication Critical patent/AU4774197A/en
Application granted granted Critical
Publication of AU724645B2 publication Critical patent/AU724645B2/en
Assigned to ABBOTT GMBH & CO. KG reassignment ABBOTT GMBH & CO. KG Alteration of Name(s) in Register under S187 Assignors: KNOLL AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Analogue/Digital Conversion (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU47741/97A 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels Ceased AU724645B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9619961 1996-09-25
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005040 WO1998013034A1 (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Publications (2)

Publication Number Publication Date
AU4774197A AU4774197A (en) 1998-04-17
AU724645B2 true AU724645B2 (en) 2000-09-28

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47741/97A Ceased AU724645B2 (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Country Status (26)

Country Link
US (1) US6187820B1 (enExample)
EP (1) EP0973511B1 (enExample)
JP (1) JP4143126B2 (enExample)
KR (1) KR100573333B1 (enExample)
CN (1) CN1173696C (enExample)
AT (1) ATE239459T1 (enExample)
AU (1) AU724645B2 (enExample)
BG (1) BG64472B1 (enExample)
BR (1) BR9711411A (enExample)
CA (1) CA2266378C (enExample)
CZ (1) CZ291879B6 (enExample)
DE (1) DE69721833T2 (enExample)
DK (1) DK0973511T3 (enExample)
ES (1) ES2199354T3 (enExample)
GB (1) GB9619961D0 (enExample)
HU (1) HU224711B1 (enExample)
IL (1) IL128820A (enExample)
NO (1) NO991424L (enExample)
NZ (1) NZ334550A (enExample)
PL (1) PL190017B1 (enExample)
PT (1) PT973511E (enExample)
RU (1) RU2197959C2 (enExample)
SK (1) SK284282B6 (enExample)
TR (1) TR199900648T2 (enExample)
UA (1) UA63916C2 (enExample)
WO (1) WO1998013034A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
EP1622600A1 (en) * 2003-04-28 2006-02-08 Cipla Ltd. Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR20060080818A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098602A (en) * 1981-04-06 1982-11-24 Boots Co Plc Therapeutic agents
EP0282206A1 (en) * 1987-02-28 1988-09-14 The Boots Company PLC Arylcyclobutylalkylamine-derivative for the treatment of Parkinson's disease
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098602A (en) * 1981-04-06 1982-11-24 Boots Co Plc Therapeutic agents
EP0282206A1 (en) * 1987-02-28 1988-09-14 The Boots Company PLC Arylcyclobutylalkylamine-derivative for the treatment of Parkinson's disease
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine

Also Published As

Publication number Publication date
IL128820A0 (en) 2000-01-31
EP0973511B1 (en) 2003-05-07
JP4143126B2 (ja) 2008-09-03
HUP9903823A3 (en) 2000-07-28
NO991424D0 (no) 1999-03-24
BR9711411A (pt) 1999-08-17
IL128820A (en) 2001-10-31
NO991424L (no) 1999-03-24
TR199900648T2 (xx) 1999-06-21
UA63916C2 (uk) 2004-02-16
AU4774197A (en) 1998-04-17
PL332367A1 (en) 1999-09-13
CA2266378A1 (en) 1998-04-02
RU2197959C2 (ru) 2003-02-10
CA2266378C (en) 2007-02-13
HU224711B1 (en) 2006-01-30
JP2001500883A (ja) 2001-01-23
NZ334550A (en) 2000-09-29
DE69721833T2 (de) 2003-12-24
ES2199354T3 (es) 2004-02-16
PT973511E (pt) 2003-08-29
BG103249A (bg) 1999-09-30
CN1173696C (zh) 2004-11-03
PL190017B1 (pl) 2005-10-31
GB9619961D0 (en) 1996-11-13
HUP9903823A2 (hu) 2000-06-28
KR100573333B1 (ko) 2006-04-24
SK284282B6 (sk) 2004-12-01
DE69721833D1 (de) 2003-06-12
EP0973511A1 (en) 2000-01-26
KR20000048567A (ko) 2000-07-25
CZ291879B6 (cs) 2003-06-18
US6187820B1 (en) 2001-02-13
BG64472B1 (bg) 2005-04-30
WO1998013034A1 (en) 1998-04-02
ATE239459T1 (de) 2003-05-15
CN1231605A (zh) 1999-10-13
DK0973511T3 (da) 2003-08-25
SK32099A3 (en) 1999-12-10
CZ93299A3 (cs) 2000-07-12

Similar Documents

Publication Publication Date Title
AU724645B2 (en) Use of sibutramine analogues to lower lipid levels
AU724488B2 (en) Use of sibutramine analogues to prevent the development of diabetes
US5459164A (en) Medical treatment
AU722129B2 (en) Medical treatment
US6376552B1 (en) Treatment of gallstones
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
US20050113457A1 (en) Treatment of neuropathic pain or fibromyalgia
US6288125B1 (en) Treatment of hiatial hernia
AU3893200A (en) Treatment of osteoarthritis
US6433020B1 (en) Treatment of cardiovascular disease
MXPA99002633A (en) Use of sibutramine analogues to lower lipid levels
WO2000056312A1 (en) Treatment of pulmonary hypertension
AU3894400A (en) Treatment of hiatial hernia
AU3632000A (en) Treatment of certain cancers associated with weight gain
AU4172900A (en) Weight loss after pregnancy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ABBOTT GMBH AND CO. KG

Free format text: FORMER OWNER WAS: KNOLL AKTIENGESELLSCHAFT